Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2026-09-17 17:41:13 ET · period of report 2026-09-15 · accession 0001816952-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 17:41 | 2026-09-15 | MLYS | Karydas Daphne | Dir | M - OptEx | $12.02 | +3,000 | 9,200 | +48% | +$36.1K |
| DT | 2026-09-17 17:41 | 2026-09-15 | MLYS | Karydas Daphne | Dir | S - Sale+OE | $28.58 | -3,000 | 6,200 | -33% | -$85.7K |
| DT | 2026-09-17 17:41 | 2026-09-15 | MLYS | Karydas Daphne | Dir | M - OptEx | $0.00 | -3,000 | 35.0K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 3,000 | $12.02 | 9,200 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. |
| 2 | Common | Common Stock | 2026-09-15 | S | D | 3,000 | $28.58 | 6,200 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. |
| 3 | Derivative | Stock Option | 2026-09-15 | M | D | 3,000 | $0.00 | 35,000 | D | $12.02 · — to 2033-09-13 | 3,000 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. (F2) The stock option vests in 36 monthly installments beginning on October 13, 2023. |